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The HIV-1 accessory protein Vpr induces G2 cell cycle arrest and apoptosis. Previous studies indicate
that the induction of G2-arrest requires the localization of Vpr to the nuclear envelope. Here we show
that treatment of Vpr-expressing HeLa cells with the caspase 3 inhibitor Z-DEVD-fmk induced
accumulation of Vpr at the nuclear lamina, while other proteins or structures of the nuclear envelope
were not inﬂuenced. Furthermore, Z-DEVD-fmk enhances the Vpr-mediated G2-arrest that even
occurred in HIV-1NL4–3-infected T-cells. Mutation of Pro-35, which is important for the integrity of
helix-a1 in Vpr, completely abrogated the Z-DEVD-fmk-mediated accumulation of Vpr at the nuclear
lamina and the enhancement of G2-arrest. As expected, inhibition of caspase 3 reduced the induction of
apoptosis by Vpr. Taken together, we could show that besides its role in Vpr-mediated apoptosis
induction caspase 3 inﬂuences the localization of Vpr at the nuclear envelope and thereby augments
the Vpr-induced G2-arrest.
& 2012 Elsevier Inc. All rights reserved.Findings
Background
The 96 amino acid Vpr is a virion-associated (Paxton et al.,
1993), nucleo-cytoplasmic shuttling protein (Sherman et al., 2001)
that is highly conserved among primate lentiviruses. Vpr is
reported to exhibit numerous biological activities including nuclear
localization (Sherman et al., 2001), induction of apoptosis (Roshal
et al., 2001), and protein transduction through cell membranes
(Henklein et al., 2000). Another well-established biological func-
tion of Vpr is its ability to cause HIV-1-infected proliferating CD4þll rights reserved.
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rt).T-cells to undergo an arrest or delay at the G2 cell cycle checkpoint
(Jowett et al., 1995). A potential explanation for the obvious
paradigm that Vpr prevents proliferation of infected T-cells by
arresting them in the G2-phase was provided by the observation
that viral gene expression is optimal in the G2-phase and that Vpr
can increase virus production by delaying cells at this stage of the
cell cycle (Goh et al., 1998). However, the function of the G2-arrest
for HIV-1 replication is still not fully understood.
In an earlier report it was suggested that localization of Vpr at
the nuclear envelope (NE) is strictly required for its capability to
induce G2 cell cycle arrest (Di Marzio et al., 1995; Jacquot et al.,
2007). Point mutations within the helix a-1 of Vpr (L23F, K27M)
disrupted the binding to the nuclear lamina and thus abrogated
Vpr-mediated G2-arrest (Jacquot et al., 2007). Another important
function of Vpr is the induction of apoptosis in HIV-1 infected
cells via destabilization of the mitochondrial membrane leading
to cytochrome C release and activation of the caspase 9/3 path-
way (Andersen et al., 2008; Votteler et al., 2007). During induc-
tion of apoptosis, caspase 3 is translocated from the cytoplasm
into the nucleus via active transport through nuclear pores
(Kuwana et al., 1998; Yasuhara et al., 1997). Generally, the
induction of apoptosis and activation of the caspase 9/3 cascade
causes changes in the diffusion limit of nuclear pores (Buendia
et al., 1999; Faleiro and Lazebnik, 2000). Considering the observa-
tion that both caspase 3 and Vpr, were shown to inﬂuence the
diffusion limit of the nuclear pore complex (Faleiro and Lazebnik,
S. So¨rgel et al. / Virology 432 (2012) 444–451 4452000; Sherman and Greene, 2002), and the fact that localization
of Vpr at the NE is important for induction of G2-arrest (Fouchier
et al., 1998; Jacquot et al., 2007; Le Rouzic and Benichou, 2005;
Popov et al., 1998), we set out to investigate whether caspase
3-inhibition affects sub-cellular localization and activities of Vpr
in apoptosis and G2-arrest induction.Fig. 1. Sub-cellular localization of Vpr: HeLa cells were transiently transfected
with pCMV-FLAG-Vpr constructs. FLAG-Vpr was stained with a FLAG-speciﬁc,
FITC-conjugated antibody (green signal). Nuclear compartments were counter-
stained with DAPI (blue signal). Cells in (B), (D), (F) were treated with Z-DEVD-
fmk. Controls in (A), (C), (E) were treated with DMSO for solvent control.Results
Caspase 3-inhibition causes accumulation of Vpr at the NE
In order to investigate the impact of caspase 3-inhibition on
localization and function of Vpr the cell permeable, speciﬁc
caspase 3 inhibitor Z-DEVD-fmk was used. This compound irre-
versibly inhibits the activation of caspase 3 (Garcia-Calvo et al.,
1998). To analyze the sub-cellular localization of Vpr, HeLa cells
were transiently transfected with plasmids expressing N-termin-
ally FLAG-tagged Vpr (wt, L23F, P35A) (Votteler et al., 2007) and
treated with 40 mM Z-DEVD-fmk for 24 h. Cells were then ﬁxed,
permeabilized, stained with a FLAG-speciﬁc, FITC-conjugated
antibody and subjected to confocal laser scanning microscopy.
Structures of the nucleus were stained with DAPI. Normal sub-
cellular distribution of wt Vpr was observed in the nucleus and
the cytoplasm as described earlier (Fig. 1A) (Le Rouzic and
Benichou, 2005). In contrast to previous reports (Jacquot et al.,
2007), in our experimental set-up it was not possible to detect a
fraction of wt Vpr at the NE. This might be explained by the
different protocols used for microscopy and was also observed by
others (Belzile et al., 2010). However, and most intriguingly,
treatment of cells with Z-DEVD-fmk for 24 h induced a strong
perinuclear rim staining of Vpr that localized at the outer lines of
the nuclear DAPI staining. This most likely represents the accu-
mulation of Vpr at the NE that parallels with reduced levels of Vpr
in the nucleus (Fig. 1B). This phenomenon not only occurred in
single cells, but was the predominant phenotype for cells treated
with Z-DEVD-fmk (Fig. 2A).
As shown previously (Jacquot et al., 2007), the VprL23F mutant
was no longer able to bind to the NE (Fig. 1E) and, in contrast to
wt Vpr, showed no accumulation at the NE upon Z-DEVD-fmk
treatment, indicating that this accumulation of Vpr at the NE
depends on a speciﬁc interaction between Vpr and components of
the NE (Fig. 1F). It was suggested that the N-terminal helix a-1
somehow mediates the binding of Vpr to the NE (Jacquot et al.,
2007). Thus, we further tested the inﬂuence of helix a-1 using our
previously characterized VprP35A mutant (Votteler et al., 2007).
In this mutant helix a-1, which is delineated by the C-terminal
Pro-35 in wt Vpr, is extended towards the C-terminus resulting in
a reduced half life and virion incorporation of the protein
(Votteler et al., 2007). Though, in contrast to the VprL23F mutant,
the VprP35A mutant contains a wt sequence of the helix a-1
(Votteler et al., 2007) and induces G2 cell cycle arrest at the level
of the wt protein (Fig. 4C) (Ardon et al., 2006; Votteler et al.,
2007). However, mutation of Pro-35 to alanine renders the
mutant insensitive to caspase 3-inhibition and abrogates the
accumulation of Vpr at the NE (Fig. 1D), indicating that the effect
of caspase 3-inhibition is speciﬁc for wt Vpr.
In order to exclude an unspeciﬁc effect of Z-DEVD-fmk on the
structure and integrity of the nuclear lamina and the localization
of the nuclear pores, HeLa cells were stained with antibodies
speciﬁc for the nuclear lamina and the nuclear pore complex. The
structure of the nuclear lamina and the localization of the nuclear
pore complex remained unchanged upon Z-DEVD-fmk treatment
(Fig. 2B and C; ﬁrst column).
To examine the localization of another protein that binds
to the NE, HeLa cells were transfected with the nuclear porelocalizing protein RanGAP which was fused to eGFP (Joseph et al.,
2002) and cells were treated with Z-DEVD-fmk. Besides its
cytoplasmatic localization, RanGAP co-localizes at the nuclear
pore complex (Fig. 2C) (Matunis et al., 1996). However, and in
contrast to Vpr, inhibition of caspase 3 did not change the
localization of this NE-associated protein (Fig. 2B and C), indicat-
ing that the Z-DEVD-fmk effect is speciﬁc for Vpr.
Z-DEVD-fmk treatment affects neither the half life and the virion
incorporation of Vpr nor its contribution to virus replication
Having shown that treatment of cells with Z-DEVD-fmk
enhances the perinuclear localization of Vpr without changing
the overall structure of the NE, we next wanted to analyze
whether caspase 3-inhibition inﬂuences the stability and virus-
incorporation of Vpr. Although the localization of wt Vpr was
affected by Z-DEVD-fmk, its half life (Fig. 3A) and virion in-
corporation (Fig. 3B) is not dependent on caspase 3-activity.
The mutant VprP35A, which does not change its localization upon
Z-DEVD-fmk treatment (Fig. 1) was also not affected by caspase
Fig. 2. Sub-cellular localization of Vpr: (A) Greater section of HeLa cells with or
without Z-DEVD-fmk treatment. (B), (C) Localization of RanGAP after caspase
3-inhibition. HeLa cells were transfected with peGFP-RanGAP (Joseph et al., 2002),
treated with Z-DEVD-fmk for 24 h and stained with (B) Lamin A/C antibody (red
signal), speciﬁc for the nuclear lamina, or (C) Mab414 antibody (red signal),
speciﬁc for the nuclear pore complex. Nuclear compartments were counterstained
with DAPI (blue signal). Green signal: eGFP-RanGAP.
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and B). As shown earlier, due to the structural changes induced by
the P35A mutation, the VprP35A protein is not efﬁciently incor-
porated into budding virions (Fig. 3B) (Votteler et al., 2007).
To exclude an unspeciﬁc or cytotoxic effect of Z-DEVD-fmk,
cell viability was tested in HeLa cells using a WST-1 assay,
demonstrating that the concentration of 40 mM Z-DEVD-fmk
showed no adverse effects (Fig. 3C).
As induction of G2-arrest was postulated to enhance replica-
tion of HIV-1 (Goh et al., 1998), we ﬁnally wanted to test whether
caspase 3-inhibition somehow affects Vpr-dependent replication
of HIV-1. Because accessory proteins like Vpr particularly deploy
their function in primary cells, monocyte derived macrophages
(MDM) and human PBMCs were infected with HIV-1NL4-3-derived
X4- or R5 tropic viruses and treated with Z-DEVD-fmk. However,
virus replication was not affected by caspase 3-inhibition, irre-
spectively of the co-receptor tropism (Fig. 3D). Studies in PBMCs
and MDMs were repeated at least three times with the same
experimental outcome. Of note, replication studies were alsoperformed in permanent T-cell culture (Jurkat), exhibiting the
same result as observed in primary human cells (data not shown).
Nevertheless, we cannot fully exclude a possible inﬂuence of
caspase 3-inhibition on HIV-1 replication as a result of augmen-
ted Vpr-induced G2 cell cycle arrest.Induction of G2 cell cycle arrest by Vpr is increased under caspase
3-inhibition
Considering that localization of Vpr at the NE is important for
induction of Vpr-mediated G2-arrest (Jacquot et al., 2007), it was
legitimate to ask whether or not the increased accumulation of
Vpr at the NE after Z-DEVD-fmk treatment would affect this
major function of Vpr. We also included the mutant VprP35A, as it
is capable of inducing G2-arrest (Ardon et al., 2006; Votteler et al.,
2007) while it is insensitive to Z-DEVD-fmk treatment in terms of
localization at the NE (Fig. 1).
To investigate the Vpr-induced cell cycle arrest, Jurkat T-cells
were infected with either wt HIV-1NL4-3, the VprP35A mutant
thereof, or a vpr-deletion-variant (HIV-1NL4-3Dvpr). Cells were
treated with Z-DEVD-fmk starting at 2 h post infection and medium
as well as inhibitor were replaced every 3rd day. At peak of infec-
tion, cells were stained with a FITC-labelled, monoclonal anti-p24
antibody to gate for HIV-1-infected cells by ﬂow cytometry. The cell
cycle state was quantiﬁed by DNA staining. As shown in Fig. 4B,
the G2-arrest induction observed for wt HIV-1NL4-3-infected cells
was considerably elevated during caspase 3-inhibition compared to
the untreated control (Fig. 4A). Cells infected with HIV-1NL4-3Dvpr
showed an overall reduced G2-arrest level (Fig. 4E), which was
not enhanced upon Z-DEVD-fmk treatment (Fig. 4F). This in-
dicates that the enhanced G2-arrest under caspase 3-inhibition
is speciﬁc for Vpr and does not result from unspeciﬁc effects of
the inhibitor.
Consistent with previous reports (Ardon et al., 2006; Votteler
et al., 2007), and in contrast to the mutant VprL23F (Jacquot et al.,
2007) the HIV-1NL4-3VprP35A mutant still induced G2-arrest at
levels comparable to wt Vpr (Fig. 4C). However, caspase 3-inhibi-
tion did not increase the level of G2-arrest induced by VprP35A.
This further conﬁrms the notion that NE localization of Vpr is
closely linked to G2-arrest induction, as localization of VprP35A
was shown to be insensitive to Z-DEVD-fmk (Fig. 4D). This effect
might be consequent to the fact that the P35A mutation did not
destroy but rather extend helix a-1 in Vpr (Votteler et al., 2007).
One possible explanation for the phenomenon could also be that
the inhibition of apoptosis would be the underlying reason for the
augmentation of G2 arrest upon caspase 3-inhibition since more
cells would survive in an acutely infected stage. However, if this
was the case, the mutant VprP35A, which does not respond to
Z-DEVD treatment in terms of G2-arrest, yet is active in terms of
apoptosis as wt Vpr (Votteler et al., 2007), would show the same
augmentation in G2-arrest induction upon caspase 3 inhibition as
the wt protein. According to three independent studies, the mean
increase of wt Vpr induced G2 cell cycle arrest upon caspase
3-inhibition was 12.19% with a standard deviation (SD) of 1.66. In
contrast, a change in G2-arrest of 0.32% was observed for the
VprP35A virus with an SD of 3.77. The Dvpr virus revealed a
change in G2-arrest of 1.62% upon Z-DEVD-fmk treatment with
an SD of 0.37.
Taken together and in accordance with previous data (Jacquot
et al., 2007), we now demonstrate that NE localization of Vpr is
important for G2-arrest induction and that enhanced localization
of Vpr at the NE upon caspase 3-inhibition leads to an augmenta-
tion of the Vpr-mediated G2-arrest in HIV-1 infected Jurkat
T-cells.
Fig. 3. Effect of Z-DEVD-fmk on functions and properties of Vpr: (A): Left: stability of Vpr under Z-DEVD-fmk treatment. HeLa cells were transiently transfected with FLAG-
Vpr expression plasmids. Protein half life was examined by Western blot after blocking protein de novo synthesis 24 h post transfection (0 h). Human ribosomal P-Antigen
(Rib. P) was used for loading control. Right: densitometric quantiﬁcation of Vpr-speciﬁc bands by image analyzing software (AIDA). (B) Vpr incorporation into HIV-1 virions
under caspase 3-inhibition. Virus-like particles (VLPs) were pelleted from supernatants of HeLa cells co-transfected with an env- and vpr-deﬁcient HIV-1NL4-3 sub-clone
(Schubert et al., 1999) and FLAG-Vpr expression plasmids containing the indicated mutations. 48 h post transfection VLPs and cell lysates were analyzed for Vpr and CA by
speciﬁc antibodies in Western blot. (C) Cell viability assay (WST-1) in HeLa cells for Z-DEVD-fmk concentrations up to 100 mM. (D) Replication proﬁles of X4- and R5-tropic
HIV-1NL4-3 (NL4-3 R5: sub-clone coding for the 005pt135 V3 region in env; (Papkalla et al., 2002)) in PBMCs (upper diagram) and monocyte derived macrophages (MDM;
lower diagram), analyzed for viral Reverse Transcriptase activity. R5-tropic strains are depicted in red and blue, X4-tropic strains are shown in light blue and yellow.
Uninfected cells are printed in dark blue and brown. Z-DEVD-fmk treatment: red, yellow and brown graph.
Fig. 4. Effect of caspase 3-inhibition on Vpr-induced G2-arrest: FACS analysis of Jurkat T-cells for DNA content and cell cycle. Cells were infected with HIV-1NL4-3 and Vpr
mutants thereof and treated with Z-DEVD-fmk 2 h post infection. At peak of replication cells were ﬁxed and permeabilized with 1% PFA and 0.1% Tween20 and stained
with anti-p24-FITC and ToPro3-iodite (DNA) for FACS-analysis. (B), (D), (F) Infected Jurkat T-cells, treated with Z-DEVD-fmk. (A), (C), (E) DMSO-treated, infected Jurkat
T-cells. Values at G0–G1 and G2-M peaks indicate the percentage of infected cells measured in the indicated cell cycle state.
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and detection of Vpr, localization studies have been
performed in HeLa cells transfected with Vpr expression
plasmids, while cell cycle was monitored in HIV-1 infected
T-cells.Induction of apoptosis by Vpr is down regulated by caspase
3-inhibition
Previous reports suggest that G2-arrest induction by Vpr
might be linked to Vpr’s pro-apoptotic activity (Andersen et al.,
S. So¨rgel et al. / Virology 432 (2012) 444–4514482005). Therefore, the apoptosis induction by Vpr was analyzed
under caspase 3-inhibition. HeLa cells were transiently trans-
fected with FLAG-Vpr-IRES-eGFP constructs and treated with
Z-DEVD-fmk. Cells were then gated for eGFP in ﬂow cytometry
and analyzed for Annexin V-staining (Fig. 5A). For both, Vpr- and
VprP35A-expressing cells, apoptosis induction was strongly
reduced after caspase 3-inhibition. This indicates that Vpr-
induced apoptosis requires, at least partially, caspase 3-activity.
In consistency, Vpr-induced apoptosis was not completely abro-
gated even in the presence of 100 mM Z-DEVD-fmk (data not
shown). Thus, at least a certain part of the Vpr-induced apoptosisFig. 5. Effect of caspase 3-inhibition on Vpr-induced apoptosis: (A) HeLa cells
were transfected with FLAG-Vpr-IRES-eGFP expression plasmids and treated with
40 mM Z-DEVD-fmk for 24 h. After incubation cells were stained for Annexin V and
subjected to FACS analysis. Apoptosis induction was examined by detection of
Annexin V signal in eGFP-expressing (Vpr-positive) cells. Apoptosis levels of
untreated cells were set to 100%. (B) HeLa cells were transfected with FLAG-Vpr
expression plasmids and treated with Z-DEVD-fmk for 24 h. Lanes ‘‘Mock’’ show
cells transfected with an empty vector for control. Cell lysates were subjected to
Western blot analysis and stained for PARP-1 (116 kDa) and its cleavage products
(86 kDa) as well as caspase 3 (35 kDa) and its cleavage products (17 kDa, active
caspase 3). For expression control and loading control the blot was stained with
anti-Vpr and anti-ß-actin antibody. (C) Densitometric analysis of PARP-signal in
Western blot shown in Fig. 5B.seems to be triggered by caspase 3-independent pathways.
Furthermore, the inﬂuence of caspase 3-inhibition on Vpr-
mediated apoptosis induction seems to be independent of Pro-
35, as this mutant is sensitive to Z-DEVD-fmk treatment in terms
of cell death other than observed for sub-cellular localization and
G2-arrest induction.
The same result was obtained by Western blot analysis of
PARP1-cleavage in pCMV-FLAG-Vpr transfected HeLa cells. The
PARP-cleavage is clearly reduced by caspase 3-inhibition (Fig. 5B).
In addition, the Western blot was stained with an antibody
against caspase 3 (Pro-form) and its cleavage products resulting
from activation of caspase 3. Treatment with the caspase 3 inhi-
bitor Z-DEVD-fmk strongly reduced the signal for cleaved caspase
3 as indicated in Fig. 5B.
Although it cannot be completely excluded that apoptosis and
G2-arrest induction by Vpr are functionally related to each other,
we could show that caspase 3-inhibition causes accumulation of
Vpr at the nuclear envelope dependent on the integrity of helix a-1
and that this elevates the Vpr-mediated G2-arrest in HIV-1-
infected cells while apoptosis induction was not elevated.Discussion
The induction of G2 cell cycle arrest is one of the most
prominent functions of Vpr and was intensively investigated over
the past years (Goh et al., 1998; Hrecka et al., 2007; Lai et al.,
2005; Roshal et al., 2003; Zimmerman et al., 2004). Although
many details about the underlying mechanism were described,
the cellular target that regulates the Vpr-mediated G2-arrest has
not been unravelled. G2 arrest induction of Vpr depends on the
interaction of Vpr with Cullin 4A via binding to VprBP (DCAF1)
and DDB1 (Hrecka et al., 2007). In this complex Vpr most likely
acts as a substrate receptor for Cul4A, which in turn induces
degradation of a yet unknown cell cycle regulator. It is not fully
elucidated in which cellular compartment the complex is cataly-
tically active so far. However, there is evidence that the complex
has to be linked to the nuclear envelope (Belzile et al., 2007, 2010;
DeHart et al., 2007; Hrecka et al., 2007; Schrofelbauer et al., 2007;
Tan et al., 2007) and Cul4A/DDB1/DCAF1/Vpr aggregates have
also been observed inside the nucleus (Belzile et al., 2010).
In addition, it was shown that the binding of Vpr to the nuclear
envelope via interaction with the nucleoporin hCG1 seems to play
an important role for G2-arrest induction (Jacquot et al., 2007).
Vpr mutants that are no longer able to bind to the NE showed an
impaired G2-arrest function (Jacquot et al., 2007). The binding
region of Vpr to the NE was mapped to the N-terminal helix a-1 in
Vpr. Mutations within the sequence of the Helix (VprL23F and
VprK27M) abrogated the binding of Vpr to the NE and showed a
strongly reduced arrest of the cell cycle (Jacquot et al., 2007).
However, G2-arrest function of Vpr is not solely mapped to the
N-terminus of the protein as mutations of certain amino acids in
the C-terminus of Vpr (R80 and R90) also lead to an abrogation of
G2-arrest function. However, these mutants are still capable of
binding to hCG1 (Jacquot et al., 2007).
As it was legitimate to hypothesize that there might be other
cellular factors that regulate the binding of Vpr to the nuclear
envelope, we analyzed the inﬂuence of caspase 3 on Vpr localiza-
tion, as it regulates nuclear pore morphology during apoptosis and
thereby it might inﬂuence Vpr localization in cell, particularly since
Vpr is capable of shuttling through the nuclear envelope (Bolton
and Lenardo, 2007; Depienne et al., 2000; Di Marzio et al., 1995; Lu
et al., 1993; Subbramanian et al., 1998; Yao et al., 1995; Zhao et al.,
1994). Our data indicate that Vpr’s localization at the NE is
augmented by caspase 3-inhibition, while the amount of Vpr in
the nucleus is reduced. This effect of Z-DEVD-fmk seems to be
S. So¨rgel et al. / Virology 432 (2012) 444–451 449speciﬁc for Vpr as the localization of another NE-associated protein,
RanGAP, is not inﬂuenced by caspase 3-inhibition. In addition, no
inﬂuence of the inhibitor could be observed on the morphology of
the nuclear lamina and the allocation of the nuclear pores. These
results further indicate that the regulation of the sensitivity of Vpr
to caspase 3-activity is related to an intact sequence and structure
of helix a-1. As already shown by others, point mutations within
the a-1 (e.g., VprL23F) abrogate the binding of Vpr to the NE
(Jacquot et al., 2007). Furthermore, this reduced binding could not
be recovered by treatment with Z-DEVD-fmk further supporting the
role of helix a-1. This was also conﬁrmed by results for the VprP35A
mutant, other than VprL23F, that mutant harbours an intact
sequence of helix a-1. However, mutation of Pro-35 results in an
elongation of the helix towards the C-terminus of the molecule and
a signiﬁcant global change of the structure of Vpr (Votteler et al.,
2007). In contrast to VprL23F, the VprP35A mutant is still able to
induce G2-arrest (Ardon et al., 2006; Votteler et al., 2007), and most
likely binds to the NE. However, the changed structure, caused by
the P35A mutation, somehow renders the VprP35A mutant insen-
sitive to caspase 3-inhibition as it does not accumulate at the NE
upon Z-DEVD-fmk treatment.
In agreement with the fact that reduced Vpr accumulation at
the NE abrogates G2-arrest induction (Jacquot et al., 2007), we
could show that augmented accumulation of Vpr at the NE
enhances the G2-arrest induction by Vpr in infected Jurkat T-cells.
Due to the limited expression level, detection of Vpr in infected
T-cells by confocal microscopy was not possible. Nevertheless, we
extrapolate from data in HeLa cells treated with Z-DEVD-fmk that
the enhanced G2-arrest induction after caspase 3-inhibition is linked
to the accumulation of Vpr at the NE and should also occur in HIV-1
infected cells. This is further in consistency with the fact that
VprP35A is insensitive to caspase 3-inhibition in both functions,
localization at the NE and G2-arrest induction. In addition, the data
for VprP35A indicate that the augmentation of G2-arrest induction is
not due to the rescue of infected cells by inhibiting apoptosis. If this
was true, G2-arrest induction by VprP35A would have been elevated
upon Z-DEVD-fmk treatment.
Furthermore, data for reduced apoptosis induction by both Vpr
variants under caspase 3-inhibition indicate that this function
most probably is not linked to G2-arrest induction that is elevated
by Z-DEVD-fmk treatment.
In addition, we show that apoptosis-induction by Vpr is mainly
regulated by caspase 3-activity. However, a certain part of Vpr
induced apoptosis seems to be dependent on another cellular
pathway due to residual apoptosis induction after Z-DEVD-fmk
treatment.
In earlier studies it was postulated that the G2-arrest provides
favourable conditions for HIV-1 replication (Brasey et al., 2003;
Goh et al., 1998; Hrimech et al., 1999). However, we were not able
to show a positive effect of caspase 3-inhibition on the replication
of HIV-1. This is most probably due to the moderate increase of
G2-arrest induction observed in infected Jurkat T-cells. In addi-
tion, since Z-DEVD-fmk ﬁrst allows to selectively regulate one of
the two major functions of Vpr in the context of a wt virus, this
might indicate that in addition to its capability to induce G2-
arrest, other functions of Vpr might be required to support HIV-1
replication in certain cell types. However, it cannot be fully
excluded that caspase 3 plays a potential role in the Vpr mediated
augmentation of G2-arrest in certain in vivo conditions, e.g., in
certain cell types, not investigated in this study.Conclusion
The localization of Vpr at the NE is dependent on the activity
of host cell caspase 3 and inﬂuences G2-arrest induction by Vpr.In addition, the sensitivity of Vpr to caspase 3 is regulated by helix
a-1. The apoptosis induction by Vpr is mainly regulated by the
caspase cascade but is not dependent on the N-terminal helix.Materials and methods
Cell culture and transfection
HeLa cells were cultivated in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) supplemented with 10% heat-inactivated fetal
calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin. For transfection, 5105 cells/well were
seeded in 6-well plates 1 d prior to transfection. The next day
transfection was performed using Lipofectamine 2000TM (Invitrogen),
according to the manufacturer’s protocol. Jurkat T-cells were culti-
vated in RPMI1640 supplemented with 10% heat-inactivated FCS,
2 mM L-glutamine, 100 U/ml penicillin and 100mg/ml streptomycin.
Western blot for protein analysis
HeLa cells were transiently transfected with the appropriate
DNA. Cells were lysed in cold RIPA buffer (50 mM Tris–HCl pH 7.4,
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholat, 0.1%
Na-SDS, 5 mM EDTA, DNAse, 1 mM PMSF and complete protease
inhibitor cocktail (Boehringer Mannheim)). The lysates were
cleared by centrifugation at 16000 g and 4 1C for 10 min. RIPA-
soluble proteins and VLPs were separated in 10% SDS/PAA gels,
according to Laemmli (1970), transferred onto PVDF membranes
(GE Healthcare) and probed with speciﬁc antibodies, followed by
enhanced chemiluminescence detection. For internal controls,
blots were stripped with 0.2% NaOH and re-incubated with
appropriate antibodies.
Viruses and virus-like particles (VLPs)
Virus stocks were produced by transient transfection of 293T
cells with pNL4-3 plasmids containing the entire HIV-1 genome
or a HIV-1NL4-3 based sub-genomic expression vector (pNLDenv;
(Schubert et al., 1995)) in which env was deleted, producing non-
infectious VLPs. Virus or VLP containing cell culture supernatant
was harvested after 48 h and, after removal of residual cells by
centrifugation, passed through a 0.45 mm pore-size ﬁlter. Virus
was pelleted through 20% (w/v) sucrose (16000 g, 4 1C, 90 min).
Virus stocks were normalized for p24 content as quantiﬁed by an
enzyme-linked immunosorbent assay (ELISA, Aalto, Dublin, Ire-
land) and aliquots were stored at 80 1C.Infection of cells
For infection of Jurkat T-cell cultures, 5106 cells were
incubated with 100 ng of p24, and incubated for 12 days, medium
and inhibitor were reconditioned every 3rd day. For infection of
human PBMCs 1 ng of p24 was applied to 2106 cells in 96-well
format, and supernatant was collected every third day post
infection. Virus replication was assessed by quantiﬁcation of the
virus-associated RT activity by [32P]-TTP incorporation using an
oligo(dT)-poly(A) template as described (Willey et al., 1988).
Flow cytometric analysis
Jurkat T-cells were infected with HIV-1NL4-3 or indicated
mutants thereof. Parallel cultures were treated with 40 mM
Z-DEVD-fmk starting 2 h post infection. Media and inhibitor were
reconditioned every 3rd day. 12 d post transfection cells were
S. So¨rgel et al. / Virology 432 (2012) 444–451450harvested, ﬁxed and permeabilized with a solution of 1% paraf-
ormaldehyde and 0.1% Tween 20 in PBS for 1 h and stained for
viral CA using the KC57-FITC-conjugated antibody (Beckman
Coulter). DNA was stained using ToPro3 (Invitrogen). DNA con-
tent was then analyzed in infected cells using a FACS LSRII (BD
Biosciences) and ModFit software (Verity Software House).
For apoptosis analysis, HeLa cells were transfected with
pCMV-FLAG-Vpr-IRES-eGFP plasmids containing the indicated
mutations. 24 h post transfection cells were removed from
culture dish and stained for Annexin V and Sytox according to
manufacturer’s protocol (Invitrogen).Confocal microscopy studies
HeLa cells were transfected with pCMV-FLAG-Vpr expression
plasmids or indicated mutants thereof. Parallel cultures were
treated with 40 mM Z-DEVD-fmk starting with transfection. 24 h
post transfection cells were ﬁxed in 3% paraformaldehyde, per-
meabilized, using 0.1% Triton X-100 in PBS and stained for FLAG-
Vpr using a FLAG-speciﬁc FITC-conjugated antibody (Sigma).
Images were obtained using a Leica TCS SP5 confocal microscope
with a 63 immersion objective.
The nuclear lamina was stained using the Lamin A/C antibody
(Pierce) and the nuclear pore complex was stained using the
antibody Mab414 (Abcam). The nucleus was counterstained using
DAPI (Invitrogen).PARP-1 cleavage assay
For PARP-1 cleavage studies cells were transfected with
pCMV-FLAG-Vpr constructs as indicated. 24 h post transfection
cells were harvested and lysed as described above and subjected
to Western blot analysis. PARP-1 and cleavage products thereof
were indicated by a PARP-1-speciﬁc antibody (Cell Signaling).
Caspase 3 and cleavage products thereof were indicated by a
caspase 3-speciﬁc antibody (Cell Signaling).Incorporation of Vpr in HIV-1 virions
HeLa cells were transiently co-transfected with the HIV-1
pNLDenvDvpr (Schubert et al., 1999) and pCMV-FLAG-Vpr con-
structs. 24 h post-transfection cells were lysed in RIPA-buffer and
virions were pelleted from culture supernatant and subjected to
immunoblot analysis using anti-FLAG (Sigma) and anti-p24 (Ser-
amun) antibodies.Determination of protein half life
HeLa cells were transfected with pCMV-FLAG-Vpr plasmids,
and 24 h post transfection cells were harvested and transferred in
RPMI containing 5 mg/ml cycloheximide, 25 mg/ml emetine and
5 mg/ml puromycin to block protein biosynthesis. Samples were
taken after 0, 1.5, 3, 6 and 9 h, and cell lysates were subjected to
Western blot analysis. Blots were probed with anti-FLAG and
anti-ribosomal P antibodies (Immunovision).Cell viability assay
For determination of the cell viability under Z-DEVD-fmk
treatment 4104 HeLa cells were seeded onto 96-well plates
and treated with the inhibitor for 24 h. Cell viability was exam-
ined using the cell proliferation reagent WST-1 (Roche) following
the protocol of the producer.Competing interests
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